![]() | Form 4 Filings | Insider Buys | Significant Buys | Penny Stocks Insider Buying | Insider Sales |
Insider Buy Sell Ratios | Stock Options | Insider Trading Stock Screener | Insider Trading Graph View | Insider Watch |
| "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise" - Peter Lynch What is insider trading>> |
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2019-06-14 Purchase | 2019-06-17 7:09 pm | Axovant Gene Therapies Ltd. | AXGT | Cheruvu Pavan CEO | 7,500 | $5.21 | $39,075 | 7,500 (Direct) | View |
2019-06-14 Purchase | 2019-06-17 7:05 pm | Axovant Gene Therapies Ltd. | AXGT | Pande Atul Director | 3,370 | $5.221 | $17,595 | 3,370 (Direct) | View |
2019-03-18 Purchase | 2019-03-19 5:15 pm | Axovant Sciences Ltd. | AXON | QVT Associates GP LLC QVT Financial Investment Cayman Ltd. 10% Owner | 6,666,667 | $1.5 | $10,000,001 | 105,952,384 (Indirect) | View |
2019-03-18 Purchase | 2019-03-19 5:06 pm | Axovant Sciences Ltd. | AXON | VIKING GLOBAL PERFORMANCE LLC Viking Global Equities LP Viking Global Equities II LP VGE III Portfolio Ltd. Viking Global Equities Master Ltd. Viking Long Fund Master Ltd. Viking Long Fund GP LLC HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner | 6,666,667 | $1.5 | $10,000,001 | 105,952,384 (Indirect) | View |
2019-03-18 Purchase | 2019-03-19 5:04 pm | Axovant Sciences Ltd. | AXON | Dexxon Holdings Ltd. Dexcel Pharma Technologies Ltd. Oren Dan 10% Owner | 6,666,667 | $1.5 | $10,000,001 | 105,952,384 (Indirect) | View |
2019-03-18 Purchase | 2019-03-19 5:03 pm | Axovant Sciences Ltd. | AXON | Machado Patrick 10% Owner | 6,666,667 | $1.5 | $10,000,001 | 105,952,384 (Indirect) | View |
2019-03-18 Purchase | 2019-03-19 5:03 pm | Axovant Sciences Ltd. | AXON | VIKING GLOBAL INVESTORS LP Viking Global Opportunities Illiquid Investments Sub-Master LP Viking Global Opportunities Portfolio GP LLC Viking Global Opportunities GP LLC HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner | 6,666,667 | $1.5 | $10,000,001 | 105,952,384 (Indirect) | View |
2019-03-18 Purchase | 2019-03-19 4:52 pm | Axovant Sciences Ltd. | AXON | SVF Investments (UK) Ltd SVF GP (Jersey) Ltd SoftBank Vision Fund L.P. SVF Holdings (UK) LLP 10% Owner | 6,666,667 | $1.5 | $10,000,001 | 105,952,384 (Indirect) | View |
2019-03-18 Purchase | 2019-03-19 4:49 pm | Axovant Sciences Ltd. | AXON | Lo Andrew 10% Owner | 6,666,667 | $1.5 | $10,000,001 | 105,952,384 (Indirect) | View |
2019-03-18 Purchase | 2019-03-19 4:18 pm | Axovant Sciences Ltd. | AXON | Roivant Sciences Ltd. 10% Owner | 6,666,667 | $1.5 | $10,000,001 | 105,952,384 (Direct) | View |
2018-12-18 Purchase | 2018-12-20 09:38 am | Axovant Sciences Ltd. | AXON | VIKING GLOBAL PERFORMANCE LLC Viking Global Equities LP Viking Global Equities II LP VGE III Portfolio Ltd. Viking Long Fund Master Ltd. Viking Long Fund GP LLC HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner | 10,000,000 | $1 | $10,000,000 | 99,285,712 (Indirect) | View |
2018-12-18 Purchase | 2018-12-20 09:37 am | Axovant Sciences Ltd. | AXON | VIKING GLOBAL INVESTORS LP Viking Global Opportunities Illiquid Investments Sub-Master LP Viking Global Opportunities Portfolio GP LLC Viking Global Opportunities GP LLC HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner | 10,000,000 | $1 | $10,000,000 | 99,285,712 (Indirect) | View |
2018-12-18 Purchase | 2018-12-20 08:57 am | Axovant Sciences Ltd. | AXON | Lo Andrew 10% Owner | 10,000,000 | $1 | $10,000,000 | 99,285,712 (Indirect) | View |
2018-12-18 Purchase | 2018-12-20 07:29 am | Axovant Sciences Ltd. | AXON | Dexxon Holdings Ltd. Dexcel Pharma Technologies Ltd. Oren Dan 10% Owner | 10,000,000 | $1 | $10,000,000 | 99,285,712 (Indirect) | View |
2018-12-18 Purchase | 2018-12-20 07:06 am | Axovant Sciences Ltd. | AXON | SVF Investments (UK) Ltd SVF GP (Jersey) Ltd SoftBank Vision Fund L.P. SVF Holdings (UK) LLP 10% Owner | 10,000,000 | $1 | $10,000,000 | 99,285,712 (Indirect) | View |
2018-12-18 Purchase | 2018-12-20 06:15 am | Axovant Sciences Ltd. | AXON | QVT Associates GP LLC QVT Offshore Ltd. 10% Owner | 10,000,000 | $1 | $10,000,000 | 99,285,712 (Indirect) | View |
2018-12-18 Purchase | 2018-12-20 06:03 am | Axovant Sciences Ltd. | AXON | Machado Patrick 10% Owner | 10,000,000 | $1 | $10,000,000 | 99,285,712 (Indirect) | View |
2018-12-18 Purchase | 2018-12-20 06:02 am | Axovant Sciences Ltd. | AXON | Roivant Sciences Ltd. 10% Owner | 10,000,000 | $1 | $10,000,000 | 99,285,712 (Direct) | View |
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2019-09-21 Option Award | 2019-09-24 5:15 pm | N/A N/A | Axovant Gene Therapies Ltd. | AXGT | Corcoran Gavin VP | 32,003 | $0 | 32,003 (Direct) | View |
2019-09-21 Option Award | 2019-09-24 5:15 pm | N/A N/A | Axovant Gene Therapies Ltd. | AXGT | Nassif David W. Principal Financial Officer | 30,120 | $0 | 30,120 (Direct) | View |
2019-09-21 Option Award | 2019-09-24 5:14 pm | N/A N/A | Axovant Gene Therapies Ltd. | AXGT | Cheruvu Pavan Principal Executive Officer | 45,181 | $0 | 45,181 (Direct) | View |
2019-07-01 Option Award | 2019-07-02 6:15 pm | N/A 2029-06-30 | Axovant Gene Therapies Ltd. | AXGT | Nassif David W. Principal Financial Officer | 150,000 | $6.42 | 150,000 (Direct) | View |
2019-07-01 Option Award | 2019-07-02 6:15 pm | N/A 2029-06-30 | Axovant Gene Therapies Ltd. | AXGT | Nassif David W. Principal Financial Officer | 75,000 | $6.42 | 150,000 (Direct) | View |
2019-06-27 Option Award | 2019-07-01 6:06 pm | N/A 2029-06-26 | Axovant Gene Therapies Ltd. | AXGT | Sundaram Senthil Vel Director | 18,750 | $6.19 | 18,750 (Direct) | View |
2019-04-15 Option Award | 2019-04-17 9:21 pm | N/A 2029-04-14 | Axovant Sciences Ltd. | AXGT | Pande Atul Director | 255,000 | $1.06 | 255,000 (Direct) | View |
2019-04-15 Option Award | 2019-04-17 9:20 pm | N/A 2029-04-14 | Axovant Sciences Ltd. | AXGT | Bickerstaff George Director | 255,000 | $1.06 | 255,000 (Direct) | View |
2019-04-15 Option Award | 2019-04-17 9:19 pm | N/A 2029-04-14 | Axovant Sciences Ltd. | AXGT | POTTER MYRTLE S Director | 255,000 | $1.06 | 255,000 (Direct) | View |
2019-04-15 Option Award | 2019-04-17 9:18 pm | N/A 2029-04-14 | Axovant Sciences Ltd. | AXGT | Torti Frank Director | 255,000 | $1.06 | 255,000 (Direct) | View |
2019-04-15 Option Award | 2019-04-17 9:17 pm | N/A 2029-04-14 | Axovant Sciences Ltd. | AXGT | Corcoran Gavin VP | 767,000 | $1.06 | 767,000 (Direct) | View |
2019-04-15 Option Award | 2019-04-17 9:17 pm | N/A 2029-04-14 | Axovant Sciences Ltd. | AXGT | Corcoran Gavin VP | 200,000 | $1.06 | 767,000 (Direct) | View |
2019-04-15 Option Award | 2019-04-17 9:15 pm | N/A 2029-04-14 | Axovant Sciences Ltd. | AXGT | Modig Berndt Director | 255,000 | $1.06 | 255,000 (Direct) | View |
2019-04-15 Option Award | 2019-04-17 9:14 pm | N/A 2029-04-14 | Axovant Sciences Ltd. | AXGT | Cheruvu Pavan CEO | 1,596,000 | $1.06 | 1,596,000 (Direct) | View |
2019-04-15 Option Award | 2019-04-17 9:14 pm | N/A 2029-04-14 | Axovant Sciences Ltd. | AXGT | Cheruvu Pavan CEO | 1,596,000 | $1.06 | 1,596,000 (Direct) | View |
2019-04-15 Option Award | 2019-04-17 9:13 pm | N/A 2029-04-14 | Axovant Sciences Ltd. | AXGT | Bazley Mathew C. General Counsel | 726,000 | $1.06 | 726,000 (Direct) | View |
2019-04-15 Option Award | 2019-04-17 9:13 pm | N/A 2029-04-14 | Axovant Sciences Ltd. | AXGT | Bazley Mathew C. General Counsel | 250,000 | $1.06 | 726,000 (Direct) | View |
2019-04-15 Option Award | 2019-04-17 9:11 pm | N/A 2029-04-14 | Axovant Sciences Ltd. | AXGT | JEFFS ROGER Director | 255,000 | $1.06 | 255,000 (Direct) | View |
2018-10-15 Option Award | 2018-10-16 6:05 pm | N/A 2028-10-14 | Axovant Sciences Ltd. | AXON | POTTER MYRTLE S Director | 150,000 | $2.37 | 150,000 (Direct) | View |